JP2021517113A5 - - Google Patents
Info
- Publication number
- JP2021517113A5 JP2021517113A5 JP2020543533A JP2020543533A JP2021517113A5 JP 2021517113 A5 JP2021517113 A5 JP 2021517113A5 JP 2020543533 A JP2020543533 A JP 2020543533A JP 2020543533 A JP2020543533 A JP 2020543533A JP 2021517113 A5 JP2021517113 A5 JP 2021517113A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- optionally substituted
- compound
- substituted
- rnai agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002413A JP7843302B2 (ja) | 2018-02-17 | 2024-01-11 | トリアルキン結合剤及び使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631683P | 2018-02-17 | 2018-02-17 | |
| US62/631,683 | 2018-02-17 | ||
| US201862646739P | 2018-03-22 | 2018-03-22 | |
| US62/646,739 | 2018-03-22 | ||
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790300P | 2019-01-09 | 2019-01-09 | |
| US62/790,300 | 2019-01-09 | ||
| PCT/US2019/018232 WO2019161213A1 (en) | 2018-02-17 | 2019-02-15 | Trialkyne linking agents and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002413A Division JP7843302B2 (ja) | 2018-02-17 | 2024-01-11 | トリアルキン結合剤及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517113A JP2021517113A (ja) | 2021-07-15 |
| JP2021517113A5 true JP2021517113A5 (enExample) | 2022-02-24 |
| JP7420727B2 JP7420727B2 (ja) | 2024-01-23 |
Family
ID=67620056
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543533A Active JP7420727B2 (ja) | 2018-02-17 | 2019-02-15 | トリアルキン結合剤及び使用方法 |
| JP2024002413A Active JP7843302B2 (ja) | 2018-02-17 | 2024-01-11 | トリアルキン結合剤及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002413A Active JP7843302B2 (ja) | 2018-02-17 | 2024-01-11 | トリアルキン結合剤及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250092072A1 (enExample) |
| EP (1) | EP3752166A4 (enExample) |
| JP (2) | JP7420727B2 (enExample) |
| CN (2) | CN111698995B (enExample) |
| AU (2) | AU2019220739B2 (enExample) |
| CA (1) | CA3089276A1 (enExample) |
| IL (1) | IL276687B2 (enExample) |
| WO (1) | WO2019161213A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2019000308A1 (en) * | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| WO2019210308A1 (en) | 2018-04-27 | 2019-10-31 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| SG11202105577TA (en) | 2019-01-09 | 2021-06-29 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| JP2022535717A (ja) | 2019-05-24 | 2022-08-10 | エンピリコ インク． | アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置 |
| JP7672394B2 (ja) * | 2019-09-03 | 2025-05-07 | アークトゥラス・セラピューティクス・インコーポレイテッド | 治療的に活性な複合体のアシアロ糖タンパク質受容体媒介送達 |
| WO2022056269A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Skeletal muscle delivery platforms and methods of use |
| CA3189065A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
| MX2023002939A (es) * | 2020-09-11 | 2023-04-11 | Arrowhead Pharmaceuticals Inc | Plataformas para el transporte de farmacos hacia el musculo esqueletico y metodos de uso. |
| JP2024516096A (ja) | 2021-04-08 | 2024-04-12 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 終末糖化産物受容体の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法 |
| MX2023014026A (es) | 2021-05-28 | 2023-12-12 | Arrowhead Pharmaceuticals Inc | Agentes de rnai para inhibir la expresion de mucina 5ac (muc5ac), composiciones de estos y metodos de uso. |
| CN113956206B (zh) * | 2021-10-25 | 2023-04-28 | 深圳湾实验室坪山生物医药研发转化中心 | 一种用于修饰蛋白质赖氨酸残基的探针及其制备方法 |
| AU2023245603A1 (en) * | 2022-03-28 | 2024-11-07 | Empirico Inc. | Modified oligonucleotides |
| US20250197859A1 (en) * | 2022-03-28 | 2025-06-19 | Empirico Inc. | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases |
| JP2025522433A (ja) | 2022-06-15 | 2025-07-15 | アローヘッド ファーマシューティカルズ インコーポレイテッド | スーパーオキシドジスムターゼ１（ＳＯＤ１）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用の方法 |
| EP4605008A1 (en) * | 2022-12-14 | 2025-08-27 | Alnylam Pharmaceuticals, Inc. | Alpha-v beta-6 integrin ligands for extrahepatic delivery |
| TW202503060A (zh) | 2023-06-13 | 2025-01-16 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ＭＭＰ７的ｓｉＲＮＡ、ｓｉＲＮＡ綴合物及其醫藥用途 |
| TW202509217A (zh) | 2023-08-24 | 2025-03-01 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ＲＡＧＥ的ＲＮＡｉ劑及其醫藥用途 |
| TW202516008A (zh) | 2023-09-27 | 2025-04-16 | 大陸商上海拓界生物醫藥科技有限公司 | 含三唑基化合物、製備方法及用途 |
| WO2025137384A1 (en) | 2023-12-20 | 2025-06-26 | Arrowhead Pharmaceuticals, Inc. | Methods and reagents for improved oligonucleotide synthesis |
| CN120309684A (zh) * | 2024-01-15 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 靶向化合物及其用途 |
| US12551569B2 (en) | 2024-03-31 | 2026-02-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use |
| WO2025265013A2 (en) | 2024-06-20 | 2025-12-26 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2021351A2 (en) * | 2006-04-28 | 2009-02-11 | Centre National de la Recherche Scientifique | Method for the synthesis of triazole-containing oligonucleotide derivatives |
| GB201313201D0 (en) * | 2013-07-24 | 2013-09-04 | Univ East Anglia | Virus Detection |
| ES2742102T3 (es) * | 2014-01-15 | 2020-02-13 | Baseclick Gmbh | Moléculas de ácido nucleico modificadas con sacárido |
| EP3294810A4 (en) * | 2015-05-12 | 2019-01-02 | Blinkbio Inc. | Silicon based drug conjugates and methods of using same |
| WO2018013525A1 (en) * | 2016-07-11 | 2018-01-18 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
| TN2019000308A1 (en) * | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
-
2019
- 2019-02-15 JP JP2020543533A patent/JP7420727B2/ja active Active
- 2019-02-15 IL IL276687A patent/IL276687B2/en unknown
- 2019-02-15 CA CA3089276A patent/CA3089276A1/en active Pending
- 2019-02-15 AU AU2019220739A patent/AU2019220739B2/en active Active
- 2019-02-15 EP EP19754398.6A patent/EP3752166A4/en active Pending
- 2019-02-15 CN CN201980013763.0A patent/CN111698995B/zh active Active
- 2019-02-15 CN CN202510149001.0A patent/CN120247964A/zh active Pending
- 2019-02-15 WO PCT/US2019/018232 patent/WO2019161213A1/en not_active Ceased
-
2024
- 2024-01-11 JP JP2024002413A patent/JP7843302B2/ja active Active
- 2024-07-16 US US18/773,657 patent/US20250092072A1/en active Pending
-
2025
- 2025-11-12 AU AU2025267360A patent/AU2025267360A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517113A5 (enExample) | ||
| JP2024028453A5 (enExample) | ||
| JP2005525427A5 (enExample) | ||
| JP2004505965A5 (enExample) | ||
| JP2009515872A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| RU2015125006A (ru) | Новые аналоги сс-1065 и их конъюгаты | |
| EP1614680A3 (en) | Process for preparing 2-iminopyrrolidine derivatives | |
| JP2005503327A5 (enExample) | ||
| JP2003519676A5 (enExample) | ||
| JP2006518704A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| JP2007500734A5 (enExample) | ||
| EP1279665A3 (en) | A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds | |
| CA2593381A1 (en) | Processes for producing 7-isoindolinequinolonecarboxylic acid derivatives and intermediates therefor, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and compositions containing the same as active ingredient | |
| JP2005503393A5 (enExample) | ||
| EP2088142A3 (en) | Dihydropyrimidines, process for their preparation and use thereof. | |
| JP2007534479A5 (enExample) | ||
| JP2000264961A5 (enExample) | ||
| JP2007538042A5 (enExample) | ||
| JP2003506455A5 (enExample) | ||
| RU2006145444A (ru) | Способ получения производных 1,4-дифенилазетидинона | |
| CA2040319A1 (en) | Sulfonylamino substituted bicyclyl hydroxamic acid derivatives | |
| CA2477720A1 (en) | Quinoline derivatives | |
| JP2002529386A5 (enExample) |